With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
The latest business developments from across Asia by Heather Hobbs To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising potential for other companies to move into export markets.
DKSH Extends Partnership with Bruker in China
the latest technologies in each of the components make the SKYSCAN series the most complete and versatile system on the market. DKSH aims to bring 3D X-ray Microscopy to customers across a range of material science industries, including geology, oil & gas exploration, polymers & composites, batteries & energy storage, pharma & packaging, automotive & aerospace, 3D printing and electronics.
Timothy Cline Oliver Hammel
DKSH Business Unit Technology and Bruker, renowned for its market leading analytical X-ray solutions, have extended their distribution agreement in China.
Last year in April, the two companies strengthened their partnership in Asia by adding a business cooperation in China with the distribution of the Bruker XRF products S2 PUMA and S2 POLAR. With the extended agreement, DKSH will also provide marketing, sales and after-sales services in China for the Bruker 3D X-ray Microscopy product line.
The 3D X-ray Microscopy product portfolio consist of three powerful benchtop systems and the SKYSCAN 2214, which is the highest resolution 3D X-ray microscope launched by Bruker, a pioneer in X-ray nano-tomography. The entire SKYSCAN series offers 3D X-ray microscopy at exceptional resolution with an unparalleled user experience. Utilising
Timothy Cline, Bruker AXS’ Vice President Global Sales, commented: “We are more than happy to announce the extension of our partnership with DKSH. DKSH has been a reliable business partner for us and has successfully grown our key products in local markets. Their wide access to industry segments, excellent market knowledge and coverage as well as their customer-centric mindset make them the right partner for us.”
Oliver Hammel, Managing Director, Business Unit Technology, DKSH China, added: “We are very pleased to extend our partnership with Bruker AXS in this promising high-tech segment. The extension of this strategic partnership proves that the state-of-the-art products and applications from Bruker paired with the unmatched sales coverage of DKSH can increase market participation and market share. This collaboration will enable us once more to enrich our product portfolio with more innovative and high-quality products and become an even more important solution provider to our customer base in China.”
52627pr@reply-direct.com
Initiative Supports Medical Education Across Asia
Swiss research-based healthcare company Novartis is to deliver bite-sized, continual learning and education support to doctors across seven countries in Asia, working in collaboration with Docquity, Southeast Asia’s largest professional network of doctors. The partnership, which fi rst started in Indonesia in 2019, was extended to the Philippines and Malaysia and now reaches into Thailand, Vietnam, Pakistan, and Bangladesh.
The COVID-19 pandemic has changed the way many industries operate and has propelled the pace of digitisation exponentially as communities across the world go virtual and this combined network
Novartis is leveraging the Docquity network to provide quality scientifi c and clinical engagement programs for doctors in the region to optimise patient care.
52861pr@reply-direct.com
Partnership Extends Cell Line offering in South Korea
Therapies Help to Repair and Prevent Disease Progression
development of next-generation stem cell therapies for future infectious respiratory disease outbreaks.
Dr Alastair Smith, Chief Executive of Avacta Group said: “I am very pleased to have extended our collaboration and license agreement with Daewoong Pharmaceutical to include the SARS-COV-2 neutralising Affi mer molecules for the treatment of COVID-19 and to create the potential to respond very rapidly in future to global virus threats.
Alastair Smith
An expansion to its original agreement with Daewoong Pharmaceutical Co and AffyXell Therapeutics has enabed Avacta to include Affi mer molecules that target viruses, such as coronaviruses, in order to develop therapies that repair the lung damage caused by COVID-19 whilst also producing neutralising Affi mer molecules to prevent the progression of the disease.
AffyXcell Therapeutics, a joint venture established in South Korea by the two companies, will engineer mesenchymal stem cells to express SARS-COV-2 neutralising Affi mer molecules in order to develop treatments for seriously ill COVID-19 patients, and will also prepare for rapid
“More broadly, one of the key areas of unmet clinical need that AffyXell can address with its next-generation mesenchymal stem cell therapies is acute pulmonary diseases such as COPD and acute respiratory distress syndrome. We, and our partners in South Korea, are very excited by the potential to develop life improving treatments for patients with these serious respiratory diseases as well as COVID-19.
Seng-ho Jeon, CEO of Daewoong Pharmaceutical and AffyXell Therapeutics, added: “It is very encouraging that AffyXell now has the opportunity to expand the application of its next-generation stem cell platform technology to target viruses. The SARS-COV-2 neutralising Affi mer to be developed in combination with AffyXell’s cell and gene technology is expected to be an innovative solution for COVID-19 patients suffering cytokine release syndrome.”
52860pr@reply-direct.com
Strengthening its presence in the Asia-Pacifi c region, Fusion Antibodies has appointed A-Frontier as exclusive supplier in South Korea for its discovery, engineering and cell line development services, which include proprietary platforms for Humanisation and Affi nity Maturation. A-Frontier is a leading supplier in Korea with its own R&D centre delivering custom antibody and protein related service.
Paul Kerr, CEO, Fusion Antibodies (Belfast) said: “We are delighted to announce this partnership with A-Frontier. We recognise their quality organisation and service provision and extensive network in the Biotech fi eld and are excited to have our platforms offered to their customers. This partnership will connect us with companies carrying out innovative work in drug discovery in South Korea. We look forward to working closely with companies to help them get to the clinic as quickly as possible without compromising the quality of their antibody.”
Eonjung Kim, CEO, A-Frontier said: “We are pleased to be able to offer these unrivalled platforms to our customers and are happy that Fusion Antibodies have selected us to deliver their services in this region.”
52729pr@reply-direct.com
Does your company sell or wish to sell laboratory products and services to the economies of Asia? Are you looking for local distributors and agents to represent you?
If so, why not advertise your products in our market-leading journal Lab Asia.
Email:
info@intlabmate.com
Business
Opportunities Asia
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84
